BMY 10-K Analysis: The $16B Earnings Recovery Is a GAAP Mirage
Bristol-Myers Squibb just reported the largest earnings swing in its history — net income reversed from a $8.9 billion loss to a $7.1 billion profit. Wall Street sees a recovery story. But the 10-K reveals free cash flow declined 7.9% to $12.8 billion, and three compression vectors — IRA pricing, an unprecedented government trade deal, and EU generics already launching — are converging on BMY's revenue faster than the market's 2028 patent cliff timeline implies. At 11.7% FCF yield, BMY is either the most undervalued cash generator in large-cap pharma or a controlled decline the market has priced correctly.